AndroGel Pediatric (Under 12) Monitoring: What Clinicians and Caregivers Need to Know

Why Pediatric Monitoring Matters for a Drug Approved Only in Adults

AndroGel is not approved for anyone under 18. Full stop. The monitoring guidance below exists because children are inadvertently exposed when they come into skin contact with an adult who applies testosterone gel and does not follow transfer-prevention steps. The FDA strengthened the Black Box Warning in 2009 specifically because post-marketing surveillance captured dozens of pediatric virilization cases, including children as young as 9 months old showing pubic hair, penile or clitoral enlargement, and accelerated growth. [1]

The T-Trials consortium (N=788 men, published in NEJM 2016) confirmed that topical testosterone raises serum testosterone reliably into the normal adult male range with once-daily application. [2] That same pharmacokinetic efficiency is what makes secondary skin-to-skin transfer dangerous for a child whose hypothalamic-pituitary-gonadal axis is developmentally suppressed. A single daily transfer event can deliver enough testosterone to produce measurable serum levels in a small child within days.

The Pediatric Endocrine Society issued a clinical practice update noting that "inadvertent androgen exposure remains one of the most common preventable causes of premature sexual development in prepubertal children presenting to pediatric endocrinology clinics." [3] That framing shapes every monitoring recommendation that follows.

Pediatricians, family medicine physicians, and any clinician caring for a child who lives with a testosterone-gel user should know these protocols. The monitoring schedule is not optional. Early detection of virilization is the difference between a fully reversible finding and a child who enters puberty two to four years ahead of peers with permanently advanced bone age.

Understanding Secondary Exposure: How Transfer Happens and Who Is at Risk

Skin-to-skin transfer is the dominant exposure route. AndroGel 1% and AndroGel 1.62% both deposit testosterone on the skin surface; the gel carrier evaporates within minutes, leaving a residue that transfers on contact. A 2010 pharmacokinetic study published in the Journal of Clinical Endocrinology and Metabolism measured serum testosterone in female partners after sleeping in the same bed as men using testosterone gel without covering the site; mean female serum testosterone rose from 23 ng/dL to 38 ng/dL within two weeks of nightly contact. [4] Children, because of their lower body weight and higher skin surface-area-to-body-mass ratio, achieve proportionally higher serum concentrations from the same transfer dose.

Transfer can also occur via contaminated clothing, bedding, or towels. The FDA's 2009 Drug Safety Communication documented cases in which children had no direct skin-to-skin contact with the applying adult but were exposed through shared fabric. [1]

Children at highest risk include:

• Infants and toddlers who are held, carried, or breastfed by a female partner of a male AndroGel user
• Children under 12 who share sleeping surfaces or hug an adult user before the site is covered
• Any child living in the same household as an AndroGel user who does not consistently cover the application site

The FDA label requires the following transfer-prevention steps: wash hands with soap and water immediately after applying AndroGel, cover the application site with clothing after the gel dries, and wash the application site with soap and water before any skin-to-skin contact with a child. [5] Adherence to all three steps reduces transfer to near-undetectable levels. Omitting any one step meaningfully increases risk.

Clinical Signs of Virilization in Children Under 12

Recognizing virilization early requires a systematic clinical checklist at every well-child visit for any child in a household with an AndroGel user. The signs below appear roughly in order of earliest to latest onset, though individual variation is wide. [3] [6]

Pubic or axillary hair (pubarche). Often the first sign. Any Tanner stage 2 or higher pubic hair in a child under 8 (girls) or under 9 (boys) should trigger a serum testosterone level that same day.

Penile or clitoral enlargement. Penile length above 6 cm stretched in a boy under 9, or clitoral length above 1 cm in a girl of any prepubertal age, is abnormal and requires urgent endocrinology referral.

Acne. Comedonal or inflammatory acne appearing before age 8 is a soft sign of androgen excess.

Accelerated linear growth. Growth velocity above 6 cm/year before age 8 in girls or age 9 in boys suggests androgen-driven growth acceleration.

Voice deepening or body odor. Later signs of significant androgen exposure. Presence means virilization has been ongoing for months.

Behavioral changes. Increased aggression or libido-like behavior in a young child is non-specific but warrants investigation when paired with any physical sign above.

The Lawson Wilkins Pediatric Endocrine Society defines premature adrenarche as Tanner stage 2 pubic hair before age 8 in girls and age 9 in boys, and any confirmed case should include exogenous androgen exposure in the differential diagnosis. [3]

The Structured Monitoring Protocol

The following framework consolidates FDA label requirements, Pediatric Endocrine Society guidance, and the clinical practice patterns of the HealthRX medical team into a single decision tree for any clinician managing a child under 12 with confirmed or suspected AndroGel exposure.

Baseline Assessment at First Known Exposure

When a clinician first learns that a child under 12 lives with an AndroGel user, the following baseline tests should be ordered at that same visit or within two weeks. [3] [5]

1. Serum total testosterone. Draw early morning (7 to 9 AM). A prepubertal child should read below 10 ng/dL. Any value above 10 ng/dL in a child under 8 (girls) or under 9 (boys) is outside the prepubertal reference range and requires pediatric endocrinology referral. [6]

2. Bone age radiograph. Left hand and wrist X-ray read by a radiologist using the Greulich-Pyle atlas. Document bone age versus chronological age. A bone age advance of more than 2 standard deviations above chronological age at baseline suggests prior androgen exposure and warrants retrospective history-taking. [7]

3. LH and FSH. Low or undetectable LH and FSH alongside an elevated testosterone confirms exogenous (not endogenous) androgen excess. Endogenous precocious puberty produces elevated LH and FSH. This distinction directs treatment. [6]

4. DHEA-S. To distinguish adrenal androgen excess from exogenous testosterone. DHEA-S is produced endogenously by the adrenal gland and is not elevated by testosterone gel transfer. An elevated DHEA-S alongside elevated testosterone suggests a mixed or endogenous picture requiring adrenal evaluation. [6]

5. Height and weight, plotted on standard growth curves. Document current growth velocity against the Centers for Disease Control and Prevention growth charts (2000). [8] This gives a baseline from which to measure acceleration at follow-up.

6. Tanner staging. Document breast, pubic hair, and genital development formally at baseline.

Monitoring Intervals During Ongoing Exposure

If exposure cannot be immediately eliminated (for example, the household is mid-transition to a non-gel testosterone formulation), monitoring continues on the following schedule. [3] [5]

Every 3 months:

• Serum total testosterone (early morning)
• Clinical Tanner staging
• Height and weight with growth velocity calculation
• Review of transfer-prevention adherence with the treating adult

Every 6 months:

• Bone age radiograph (left hand and wrist)
• LH, FSH, and DHEA-S
• Full virilization symptom review with parent or guardian

Any single abnormal result triggers immediate pediatric endocrinology referral, not a "watch and wait" approach. Bone age advancement is irreversible once the growth plates begin to fuse prematurely; a child who loses 2 years of predicted adult height due to early epiphyseal fusion cannot recover that height. [7]

Monitoring After Exposure Ends

Once the child has zero further contact with AndroGel (either through household transfer to a patch or injection formulation, or through changes in custody or living arrangements), monitoring continues for at least 12 months because residual tissue testosterone depots may continue to produce measurable serum levels for weeks. [9]

Month 1 post-exposure: Repeat serum testosterone to confirm decline toward prepubertal range.

Month 3 post-exposure: Tanner staging check; any continued progression despite confirmed testosterone normalization should trigger GnRH stimulation testing to rule out central precocious puberty triggered by the androgen exposure period.

Month 6 and Month 12 post-exposure: Bone age radiograph and growth velocity. Most soft-tissue virilization (pubic hair, clitoromegaly, penile enlargement) regresses within 3 to 6 months. Bone age advancement, however, is not reversible. If the bone age advance is significant (>2 years above chronological age), a pediatric endocrinologist may consider GnRH agonist therapy to slow further epiphyseal fusion and preserve adult height potential. [3] [7]

Laboratory Reference Ranges for Prepubertal Children

Interpreting testosterone levels in children requires pediatric-specific reference ranges, not adult ranges. The following values are drawn from published Pediatric Endocrine Society and clinical laboratory consensus guidelines. [6] [10]

• Total testosterone, prepubertal boys (Tanner 1): 1 to 10 ng/dL
• Total testosterone, prepubertal girls (Tanner 1): 1 to 10 ng/dL
• Total testosterone, early puberty (Tanner 2 boys): 18 to 150 ng/dL
• LH, prepubertal: <0.3 IU/L (basal, early morning)
• FSH, prepubertal: <2.5 IU/L (basal)
• DHEA-S, ages 6 to 8: 10 to 75 mcg/dL (sex and age-specific; use lab-specific pediatric reference interval)

A testosterone value above 10 ng/dL in a confirmed Tanner 1 child with suppressed LH and FSH is diagnostic of exogenous androgen exposure until proven otherwise. [6] Send a second confirmatory sample before referral if the clinical picture is otherwise silent, because a single outlier may reflect lab processing error. If the second sample is also above 10 ng/dL, refer same day.

Transfer-Prevention Counseling for Adults Using AndroGel

Monitoring a child is necessary but not sufficient. The root cause is transfer, and clinicians prescribing AndroGel to any adult who lives with or cares for children under 12 must provide explicit written transfer-prevention counseling at every refill visit. The FDA label mandates this disclosure. [5]

The three non-negotiable steps are:

1. Apply AndroGel only to the shoulders, upper arms, or abdomen (approved application sites). Never apply to the genitals, chest, or any area a child might contact.
2. Allow the gel to dry completely (approximately 5 minutes), then cover with a shirt before any contact with a child.
3. Wash the application site with soap and water before skin-to-skin contact with any child under 12.

A 2010 FDA-sponsored contact study showed that washing the application site before contact reduced female partner testosterone absorption by approximately 95% compared to no washing. [4] Covering alone without washing reduced transfer by roughly 50%. Washing plus covering was additive.

Clinicians should also counsel adult users to consider switching to a non-transferable formulation (subcutaneous testosterone pellets, intramuscular testosterone cypionate or enanthate, or nasal testosterone gel) when young children are in the household. Nasal testosterone gel (Natesto) deposits testosterone in the nasal mucosa only and carries no documented secondary transfer risk in published literature. [11]

When to Refer and What to Tell the Pediatric Endocrinologist

A referral to pediatric endocrinology is appropriate in any of the following situations. [3] [6]

• Serum testosterone above 10 ng/dL on two separate morning samples in a confirmed Tanner 1 child
• Any Tanner 2 or higher finding in a girl under 8 or a boy under 9
• Bone age advance of more than 1 year above chronological age at any monitoring visit
• Growth velocity above 6 cm/year in a confirmed prepubertal child
• Parent or guardian report of acne, voice change, or behavioral change consistent with androgen excess

The referral note should include: the specific AndroGel product the household contact uses (1% or 1.62%), estimated duration of exposure, transfer-prevention practices in use, all laboratory results with collection times, current Tanner stage, current and baseline height and weight, and the most recent bone age report.

The pediatric endocrinologist will typically perform a GnRH stimulation test to distinguish central precocious puberty (CPP) from peripheral (exogenous androgen-driven) precocious puberty. CPP produces a strong LH rise (>5 IU/L at 30 to 60 minutes post-GnRH). Peripheral precocious puberty from testosterone gel exposure produces a suppressed or flat LH response. Treatment diverges completely between these two diagnoses: CPP is treated with GnRH agonists such as leuprolide acetate 7.5 mg IM monthly, while testosterone-transfer precocious puberty is treated primarily by eliminating the exposure source. [3] [7]

Deliberate Off-Label Prescribing of Testosterone Gel in Children Under 12

This situation is rare and should prompt immediate specialist involvement. No FDA-approved testosterone gel formulation is indicated for children under 12. In the exceptional off-label context (for example, a pediatric endocrinologist using testosterone gel micro-dosing to treat a boy with congenital hypogonadotropic hypogonadism or Klinefelter syndrome), the monitoring parameters above apply with additional intensity. [12]

Published pediatric testosterone dosing protocols for induction of puberty in boys with delayed puberty or hypogonadism typically use injectable testosterone enanthate or cypionate, starting at 50 mg IM every 4 weeks and increasing gradually over 2 to 3 years. [12] Topical gel is not a standard choice in this age group precisely because dose precision is lower and secondary transfer to siblings or other household children is a safety concern. When a pediatric endocrinologist does elect to use a gel formulation off-label, dosing is weight-based (approximately 2 to 5 mg/day in younger adolescents), application sites are carefully selected to minimize transfer, and monitoring includes all parameters described above plus monthly serum testosterone during dose titration. [12]

The Pediatric Endocrine Society's 2023 clinical guidelines on testosterone therapy in transgender and gender-diverse youth note that "topical testosterone preparations require extra caution in household settings with other prepubertal children and should be accompanied by explicit written transfer-prevention education at every visit." [13]

Regulatory and Reporting Obligations

Any clinician who identifies a case of virilization in a child under 12 secondary to testosterone gel exposure should file a MedWatch report with the FDA. Post-marketing surveillance depends on voluntary reporting; the FDA's 2009 label change was driven almost entirely by MedWatch case accumulation. [1] [5] Filing takes approximately 15 minutes at fda.gov/safety/medwatch and contributes to the evidence base that protects other children.

Mandatory child abuse reporting is generally not triggered by accidental testosterone gel transfer when the adult user is compliant with standard-of-care prescribing and there is no evidence of intentional exposure. Each case requires clinical judgment and, when in doubt, consultation with the hospital's child protective services liaison. Intentional administration of testosterone to a child without medical indication is a different matter entirely and should be reported to child protective services immediately.

Summary of Monitoring Parameters by Visit Type

The table below consolidates all monitoring actions by visit type for quick clinical reference. Each parameter maps to the evidence cited in this article.

| Visit Type | Timing | Parameters | |---|---|---| | Baseline | At first known exposure | Serum testosterone, bone age X-ray, LH, FSH, DHEA-S, height/weight, Tanner staging | | Routine follow-up | Every 3 months | Serum testosterone, Tanner staging, height/weight, growth velocity, transfer-prevention review | | Extended follow-up | Every 6 months | All of the above plus bone age X-ray, LH, FSH, DHEA-S | | Post-exposure Month 1 | 1 month after last exposure | Serum testosterone confirmation | | Post-exposure Month 3 | 3 months after last exposure | Tanner staging, consider GnRH stimulation if progression continues | | Post-exposure Months 6 and 12 | 6 and 12 months post-exposure | Bone age X-ray, growth velocity |

Any abnormal result at any visit type triggers immediate pediatric endocrinology referral.